Credit rating agency, Credit Analysis & Research (CARE), has revised credit rating for long term debt instruments issued by Ranbaxy Laboratories from ‘AA+’ to ‘AA’. Long term instruments with ‘AA’ rating are considered to have high degree of safety regarding timely payment of financial obligations and carry very low credit risk.
The credit rating agency has however reaffirmed the ‘A1+’ rating assigned to the short term bank facilities of the company. Short term debt instruments with rating of ‘A1+’ are considered to have very strong degree of safety regarding timely payment of financial obligations and carry lowest credit risk.
Ranbaxy Laboratories is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1837.15 |
| Dr. Reddys Lab | 1271.55 |
| Cipla | 1353.85 |
| Zydus Lifesciences | 1070.90 |
| Lupin | 2351.90 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: